

Application No.: 10/002,854

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-9. (Canceled)

10. (Previously Amended) A method of inhibiting migration of calcium-sensing receptor expressing hematopoietic cells to a specific site in a subject, comprising: locally administering to a specific site in a subject in need of such treatment a calcium-sensing receptor antagonist in an amount effective to inhibit migration of calcium-sensing receptor expressing hematopoietic cells to the specific site in the subject.

11-92. (Canceled)

93. (Previously Presented) The method of claim 10, wherein the specific site is a site of inflammation.

94. (Previously Presented) The method of claim 93, further comprising co-administration of a non-calcium-sensing receptor antagonist that inhibits migration of immune cells to the site of inflammation in the subject.

95. (Previously Presented) The method of claim 94, wherein the non-calcium-sensing receptor antagonist is an antiinflammatory agent.

96. (Previously Presented) The method of claim 10, wherein the subject has an autoimmune disease.

97. (Previously Presented) The method of claim 96, wherein the autoimmune disease is rheumatoid arthritis, uveitis, insulin-dependent diabetes mellitus, hemolytic anemias, rheumatic fever, Crohn's disease, Guillain-Barre syndrome, psoriasis, thyroiditis, Graves'

Application No.: 10/002,854

disease, myasthenia gravis, glomerulonephritis, autoimmune hepatitis, or systemic lupus erythematosus.

98. (Previously Presented) The method of claim 10, wherein the subject has an abscess, a transplant, an implant, atherosclerosis, or myocarditis.

99. (Canceled)

100. (Previously Amended) the method of claim 98, wherein the hematopoietic cells are hematopoietic progenitor cells.

101-104. (Canceled)

105. (Previously Presented) The method according to any of the claims 10, 93, 98 and 100, wherein the calcium-sensing receptor antagonist is N-[(R)-2-hydroxy-3-(2-cyano-3-chlorophenoxy) propyl]-1-dimethyl-2-(2-naphthyl) ethylamine (NPS-2143).